The United Kingdom and the United States have finalized a key trade agreement that will guarantee zero duties on UK medicine shipments being sold in the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has pledged to increase expenditure on pharmaceuticals through the public health system. This move secures that duties on these key goods will stay at nothing for a period of 36 months.
This deal is in response to previous threats to hike import taxes on patented drug products, with figures floated up to 100%.
"This deal with the United Kingdom bolsters the global environment for innovative medicines and brings long-overdue fairness to transatlantic drug exports," an announcement noted.
Economic Impact
Drugs constitute one of the UK's biggest goods shipped to the America, which is clearly the largest market for leading companies like GSK and AstraZeneca.
Export figures reveal that in the year leading up to last September, the UK sold medicines totaling £11.1bn to the US. This value made up nearly one-fifth of total UK exports in that timeframe.
"This agreement secures employment, increases investment and paves the way for the UK to emerge as a international leader for medical research," a minister remarked.
Key NHS Changes
The agreement includes several notable commitments from the United Kingdom:
- Price Threshold Increase: The UK will increase the cost ceiling at which it considers new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to double total NHS spending on treatments from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The sum manufacturers must return to the NHS to prevent overspending will be limited at fifteen percent. Last year, rebates were more than 20%.
Broader Context
The pact takes place against a ongoing row between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
This friction were intensified by arguments that US customers were paying a premium for the equivalent treatments than patients in the other developed nations.
In recent months, several major pharmaceutical investments in the UK have been halted or abandoned, while major investments have been directed toward US facilities.
The Science Minister publicly accepted that the NHS had to spend more on treatments, noting that its budget allocation on drugs had declined as a percentage of its resources over the last ten years.
